Effects of Growth Hormone (GH) Treatment on Eating Regulation
Information source: Rabin Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Short Stature
Intervention: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention (Behavioral); growth hormone-Genotropin or NorditropinSimplex or "Biotropin" (Behavioral)
Phase: N/A
Status: Completed
Sponsored by: Rabin Medical Center Official(s) and/or principal investigator(s): Moshe Phillip, Professor, Principal Investigator, Affiliation: Schneider Children Medical Center
Summary
This is a two arm, randomized, prospective, intervention study in order to determine the
effects of growth hormone treatment on eating regulation and to compare between the growth
responses with or without nutritional intervention in short stature children.
The study will include 30 short stature children that are about to initiate growth hormone
treatment and will last for one year. After 4 months of treatment, children will be
randomized into two groups:
1. Control group that will continue with growth hormone treatment without any other
intervention.
2. Study group that will be a given a nutritional intervention in addition to growth
hormone treatment.
At screening visit and during the study the following parameters will be evaluated: height,
weight, growth markers in the blood and urine, child eating behavior questionnaire, blood
tests, hormonal tests and resting energy expenditure measurements.
Clinical Details
Official title: Effects of Growth Hormone Treatment on Eating Regulation and Comparison Between the Growth Responses With or Without Nutritional Intervention in Short Stature Children
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: height and weightGrowth markers
Secondary outcome: Safety laboratory parametersfood diary Resting energy expenditure measurements
Detailed description:
This is a two arm, randomized, prospective, intervention study in order to determine the
effects of growth hormone treatment on eating regulation and to compare between the growth
responses with or without nutritional intervention in short stature children.
Background:
In the last three decades children with different kinds of short stature pathologies were
treated with growth hormone. Most of the attention in growth hormone studies is focused on
the effect of the treatment on growth. Today there are very few studies that are focused on
the effect of growth hormone on eating regulations and the connection between eating
regulations and growth improvement in growth hormone treatment.
Objectives:
1. To evaluate the effect of short term growth hormone treatment on the following
parameters:
1. Appetite, food preference, amount of food and ingredients.
2. Changes in food regulations.
3. Changes in body composition.
4. Changes in resting energy expenditure.
5. Changes in hormones that are associated with appetite and with energy balance:
IGF-1,IGFBP1&3 and Ghrelin.
6. Changes in metabolic and nutritional measurements: glucose, insulin, lipid
profile, total proteins, albumin, liver functions, alkaline-phosphatase,
hemoglobin, transferrin, iron, B12, folic acid.
2. To evaluate the effect of nutritional support on growth rate in one year growth hormone
treatment.
3. To evaluate changes in growth markers in the serum and urine during growth hormone
treatment.
Methods:
The study will include 30 short stature children that are about to initiate growth hormone
treatment and will last for one year. After 4 months of treatment children will be
randomized into two groups:
1. Control group that will continue with growth hormone treatment without any other
intervention.
2. Study group that will be given a nutritional intervention In addition to growth hormone
treatment.
The nutritional intervention will include nutritional consultation and applying a personal
dietetic menu. At screening visit and during the study the following parameters will be
evaluated: height, weight, growth markers in the blood and urine, food diary, child eating
behavior questionnaire, resting energy expenditure measurements, blood tests, hormonal tests
and fasting and post-prandial levels of leptin, ghrelin, GLP-1, insulin and glucose.
Eligibility
Minimum age: 2 Years.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Height of at least 2. 0 standard deviations below the mean height for chronological
age and sex according to the 2000 standards from the Centers for Disease Control and
Prevention (CDC).
2. Children that have one of the following short stature pathologies:
1. IGHD or MPHD
2. ISS
3. SGA
3. Proper function of thyroid gland, kidney and liver
4. Prior to initiating growth hormone treatment
Exclusion Criteria:
1. Chronic diseases
2. Diseases in the digestive system.
3. Neurological diseases.
4. Malignant diseases in the past or in the present. Treated with chemotherapy or
radiation.
5. Genetic syndromes
6. Bone diseases
7. Taking chronic medicine, SSRI type, that effect the appetite and the growth hormone
signal transduction.
Locations and Contacts
Schneider Children's Medical Center, Petach-Tikva, Israel
Additional Information
Starting date: January 2008
Last updated: July 15, 2013
|